Ckd Bio (063160) - Total Assets
Based on the latest financial reports, Ckd Bio (063160) holds total assets worth ₩298.38 Billion KRW (≈ $202.21 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check Ckd Bio (063160) reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Ckd Bio - Total Assets Trend (2008–2025)
This chart illustrates how Ckd Bio's total assets have evolved over time, based on quarterly financial data. Explore how much of Ckd Bio's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Ckd Bio - Asset Composition Analysis
Current Asset Composition (December 2025)
Ckd Bio's total assets of ₩298.38 Billion consist of 45.4% current assets and 54.6% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩0.00 | 0.5% |
| Accounts Receivable | ₩34.71 Billion | 11.6% |
| Inventory | ₩96.77 Billion | 32.3% |
| Property, Plant & Equipment | ₩0.00 | 0.0% |
| Intangible Assets | ₩5.58 Billion | 1.9% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2008–2025)
This chart illustrates how Ckd Bio's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Ckd Bio market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Ckd Bio's current assets represent 45.4% of total assets in 2025, a decrease from 60.8% in 2008.
- Cash Position: Cash and equivalents constituted 0.5% of total assets in 2025, down from 9.6% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2008.
- Asset Diversification: The largest asset category is inventory at 32.3% of total assets.
Ckd Bio Competitors by Total Assets
Key competitors of Ckd Bio based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Aurobindo Pharma Limited
NSE:AUROPHARMA
|
India | Rs585.02 Billion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099
|
China | CN¥7.28 Billion |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS
|
USA | $392.01 Million |
|
Procter & Gamble Health Limited
NSE:PGHL
|
India | Rs8.94 Billion |
Ckd Bio - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.10 | 1.26 | 1.93 |
| Quick Ratio | 0.33 | 0.43 | 0.71 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩12.71 Billion | ₩25.86 Billion | ₩47.20 Billion |
Ckd Bio - Advanced Valuation Insights
This section examines the relationship between Ckd Bio's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.68 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 5.4% |
| Total Assets | ₩299.87 Billion |
| Market Capitalization | $59.56 Million USD |
Valuation Analysis
Below Book Valuation: The market values Ckd Bio's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Ckd Bio's assets grew by 5.4% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Ckd Bio (2008–2025)
The table below shows the annual total assets of Ckd Bio from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | ₩299.87 Billion ≈ $203.22 Million |
+5.40% |
| 2024-12-31 | ₩284.49 Billion ≈ $192.80 Million |
-3.16% |
| 2023-12-31 | ₩293.79 Billion ≈ $199.09 Million |
-6.02% |
| 2022-12-31 | ₩312.59 Billion ≈ $211.84 Million |
+4.71% |
| 2021-12-31 | ₩298.54 Billion ≈ $202.32 Million |
+5.32% |
| 2020-12-31 | ₩283.46 Billion ≈ $192.10 Million |
+21.48% |
| 2019-12-31 | ₩233.35 Billion ≈ $158.14 Million |
+26.46% |
| 2018-12-31 | ₩184.52 Billion ≈ $125.05 Million |
+2.81% |
| 2017-12-31 | ₩179.48 Billion ≈ $121.63 Million |
-0.79% |
| 2016-12-31 | ₩180.91 Billion ≈ $122.60 Million |
+6.02% |
| 2015-12-31 | ₩170.64 Billion ≈ $115.64 Million |
+3.38% |
| 2014-12-31 | ₩165.07 Billion ≈ $111.86 Million |
-5.94% |
| 2013-12-31 | ₩175.50 Billion ≈ $118.93 Million |
-5.35% |
| 2012-12-31 | ₩185.42 Billion ≈ $125.66 Million |
-6.49% |
| 2011-12-31 | ₩198.29 Billion ≈ $134.38 Million |
+67.66% |
| 2010-12-31 | ₩118.27 Billion ≈ $80.15 Million |
+6.30% |
| 2009-12-31 | ₩111.26 Billion ≈ $75.40 Million |
+17.30% |
| 2008-12-31 | ₩94.85 Billion ≈ $64.28 Million |
-- |
About Ckd Bio
CKD Bio Corp. engages in the manufacturing and sale of pharmaceutical products in South Korea, Europe, Asia, the Middle East, and internationally. The company is also involved in real estate leasing and related ancillary; bio, cosmetics, and health functional food; property management; advertising communication; consulting, construction, and maintenance of corporate IT systems business. It also e… Read more